BRAF+ metastatic melanoma patient on treatment

Is TAFINLAR + MEKINIST right for me?

TAFINLAR + MEKINIST is a combination therapy for BRAF-positive (also seen as BRAF+) melanoma. TAFINLAR + MEKINIST is a targeted therapy that can be used for 2 different types of melanoma treatment:

  • Adjuvant (after surgical removal) treatment of BRAF+ melanoma, to help prevent your melanoma from coming back after surgery
  • Treatment of BRAF+ melanoma that has spread to other parts of the body (metastatic) or cannot be removed by surgery

TAFINLAR, in combination with MEKINIST, should not be used to treat people with a type of skin cancer called wild-type BRAF melanoma. MEKINIST should not be used to treat people who already have received a BRAF inhibitor for treatment of their melanoma and it did not work or is no longer working.

How does TAFINLAR + MEKINIST treat my melanoma?

Medical research has shown that TAFINLAR + MEKINIST may help slow the growth of certain melanoma cancer cells with a BRAF mutation. TAFINLAR + MEKINIST has been studied in clinical trials of patients with BRAF+ melanoma (either V600E or V600K mutation-positive as determined by a US Food and Drug Administration [FDA]-approved test).


Your health care provider will only prescribe you TAFINLAR + MEKINIST after a genetic test is performed on a biopsy (sample of tissue taken for further testing) of your melanoma with a positive result indicating a BRAF mutation. When discussing treatment options with your health care provider, ask if genetic testing for BRAF mutations is right for you.

What kind of treatment is TAFINLAR + MEKINIST?

As a targeted combination therapy, TAFINLAR + MEKINIST helps inhibit out-of-control cell growth by blocking cell-growth signals associated with the BRAF gene. TAFINLAR and MEKINIST work together, with each targeting a different point in this cell-signaling pathway. TAFINLAR + MEKINIST can also affect healthy cells in the body.